Forward PE Ratio: 13.25
The forward PE ratio is 13.25 as of Thursday, July 9, 2026.
Forward PE Ratio (13.25) = Close Price ($64.70) / Consensus Forward EPS ($4.88)
GEHC Forward PE Ratio Metrics
FORWARD PE RATIO
13.25
GEHC Competitors' Forward PE Ratio
GE HealthCare Technologies Inc.
Market Cap
$29.43B
Forward PE Ratio
13.25
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.43B | 13.25 |
| Biogen Inc. (BIIB)vs › | $29.37B | 13.80 |
| ResMed Inc. (RMD)vs › | $30.24B | 18.53 |
| Moderna, Inc. (MRNA)vs › | $30.38B | N/A |
| DexCom, Inc. (DXCM)vs › | $28.18B | 28.55 |
| Veeva Systems Inc. (VEEV)vs › | $30.82B | 23.70 |
| Zoetis Inc. (ZTS)vs › | $31.48B | 10.91 |
| Mettler-Toledo International Inc. (MTD)vs › | $26.03B | 26.75 |
| Centene Corp. (CNC)vs › | $33.38B | 19.16 |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.27B | 41.06 |
Trailing vs Forward
Trailing P/E
19.8
reported TTM EPS
Forward P/E
13.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.88 implies +49.2% EPS growth vs the reported trailing $3.27.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $64.70 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $4.88 | $4.85 – $4.89 | 12 | 13.3x |
| 2027-12-31 | $5.40 | $5.17 – $5.52 | 12 | 12.0x |
| 2028-12-31 | $6.02 | $5.63 – $6.47 | 9 | 10.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for GE HealthCare Technologies Inc. (GEHC)?
- The forward PE ratio for GEHC stock is 13.25.
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini